Proteomics International LaboratoriesLtd

Proteomics International Laboratories (ASX: PIQ) has secured new intellectual property protection in Canada, after the country’s Patent Office granted a patent for its PromarkerEso blood test for esophageal adenocarcinoma.

Proteomics International Laboratories (ASX: PIQ) has announced that the US Centres for Medicare & Medicaid Services has set a US$390.75 reimbursement price for its PromarkerD predictive test for diabetic kidney disease.

Proteomics International (ASX: PIQ) has achieved a significant milestone with the granting of ISO 15189 certification for its Australian laboratory operations. The medical testing certification – which adds to Proteomics’ existing ISO 17025, ISO 13485 and CLIA certifications – will assist the company in commercialisation and clinical use of its suite of precision diagnostic tests, […]

Proteomics International Laboratories (ASX: PIQ) has officially launched its unique PromarkerD predictive test for diabetic kidney disease in Australia. PromarkerD is a clinically validated blood test that helps predict the risk of developing chronic diabetic kidney disease (DKD) in type 2 diabetes patients up to four years before clinical symptoms appear. Diabetes is the leading […]